Logo image
Sign in
Back
COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies
Journal article   Peer reviewed

COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies

Bradley J. Monk, Robert L. Coleman, Kathleen N. Moore, Thomas J. Herzog, Angeles Alvarez Secord, Ursula A. Matulonis, Brian M. Slomovitz, Saketh R. Guntupalli and David M. O'Malley
Gynecologic oncology, Vol.158(1), pp.34-36
07/01/2020
DOI: https://doi.org/10.1016/j.ygyno.2020.04.703
PMID: 32370991

Abstract

COVID-19 Oral Ovarian cancer SARS-CoV-2 Targeted therapy
•The pandemic COVID-19 requires alternative methods and thinking to keep healthcare professionals and patients safe.•In COVID-19 hot spots, oral therapies may be viable alternatives to intravenous therapies for treatment of ovarian cancer.•Minimizing patient visits to hospitals and cancer clinics may help mitigate the spread of SARS-CoV-2.

Metrics

12 Record Views

Details